P³M Advisory provides experienced portfolio, program and project leadership to help Biotech, Pharma and CRO organizations make better decisions, strengthen delivery and turn priorities into execution.
EXPLORE A FIRST DISCUSSIONBack to homepageComplex R&D portfolios rarely fail because organizations lack ideas or ambition. The difficulty is maintaining alignment between strategy, priorities, governance, resources, capacity and day-to-day execution as complexity grows.
Not just provide advice, but create clearer priorities, better decision-making, stronger visibility of resource and capacity constraints, and more reliable execution across the portfolio.
The trigger for support is different in each life-sciences environment. The approach should reflect that context.
As a biotech grows, informal ways of working can become a constraint. Typical needs include:
Large R&D organizations often need stronger orchestration across complexity. Typical needs include:
Service organizations must balance client delivery with internal portfolio discipline. Typical needs include:
The differentiator is not generic project management expertise. It is senior, hands-on life-sciences portfolio leadership from someone who has managed and analysed complex drug discovery and development portfolios and R&D project portfolios inside established organizations.
Fractional support provides experienced portfolio and PM leadership with a level of commitment tailored to the organization’s needs.
Support can move from portfolio and governance design into hands-on program delivery, rather than stopping at recommendations.
Experience spans drug discovery, R&D portfolio governance, prioritization, resource allocation, capacity planning and cross-functional programs.
Work can be structured as advisory, fractional leadership or delivery support depending on the problem and level of ownership required.
P³M Advisory is founder-led by Mauro Dionisi, with Project and Portfolio Management experience spanning AXXAM, Evotec and Stevanato Group, from R&D portfolio analysis to senior portfolio leadership.
Led the Project and Portfolio Management Office across portfolio governance, project execution and the PM team. Strengthened PPM processes and supported senior leadership in prioritization, resource allocation and strategic decision-making, while driving cross-functional delivery of complex drug discovery programs.
Managed the global Integrated Drug Discovery project portfolio, providing portfolio oversight and supporting executive decision-making on prioritization and capacity planning. Also served as PM Country Lead for Italy, leading the local project portfolio and Project Management team.
Managed cross-functional development projects, coordinating project plans, stakeholders, timelines and delivery across development activities.
Supported R&D portfolio analysis and management, consolidating project information to strengthen portfolio visibility, prioritization and management decision-making across product development initiatives.
Where precise metrics cannot be disclosed, the value can still be made concrete through the operational outcomes that stronger governance and delivery are designed to produce.
More explicit choices about what matters most and what should wait.
Leadership has clearer information on portfolio status, dependencies, resource pressure and capacity constraints.
Strategy is translated into governed initiatives, accountable delivery and more consistent cross-functional follow-through.
No client testimonials or unpublished quantitative claims are shown here until they can be supported by permission and verifiable evidence.
Strategic guidance on portfolio design, governance, prioritization, PM maturity and decision processes.
Senior Director / Head-level leadership to add capability, bandwidth and ownership without the commitment of a full-time executive hire.
Hands-on project or program leadership from planning through execution, governance and stakeholder alignment.
These are also the themes around which P³M Advisory can build future insights and thought leadership.
A first discussion can focus on where your current portfolio or delivery model is under pressure: prioritization, governance, resource constraints, PM capability, leadership bandwidth or a specific program that needs stronger ownership.
BOOK AN INTRODUCTORY CONVERSATIONWe use Vercel Web Analytics for aggregate visit statistics without analytics cookies. Vercel processes technical request data to distinguish visits using a temporary identifier discarded after 24 hours. Data may include the page, referrer, device and approximate location. We do not send form contents to this service. Google Analytics remains optional and only starts after you accept analytics in the banner; you can change that choice under “Analytics preferences”. Vercel data processing information.
